An article published in the journal “Cell” describes the experimentation on mice of a variant of the CRISPR/Cas9 genetic modification system to treat a number of diseases. A team of researchers from the Salk Institute for Biological Studies used a version of CRISPR/Cas9 that doesn’t modify the DNA avoiding the risk of causing unexpected mutations but can activate one or more genes creating an epigenetic therapy for diseases such as Type 1 diabetes, acute kidney disease or muscular dystrophy.